Replies to post #890 on Vascular Biogenics Ltd (VBLT)

[davidal66]

The DMSC will meet when there are 105 events and 50 % of patient in the trial have had 12 potential months of treatment. The will meet and determine of the futility criteria is met... does the drug pass futility. Then they will give the decision back to the company. In my experiences I remember with similar situations--ie CLDX, the stock is typically halted in the timeframe of the meeting/immediate aftermath, the company gets the news, issues a PR, then the stock reopens(hopefully higher =)